Luke Halpern, Associate Editor

Glucocorticoids improved outcomes for patients with Kawasaki disease at high risk of IVIG resistance without glucocorticoid-related adverse effects.

High-resolution scans can provide a picture of a patient’s brain that typical MRIs cannot, allowing for more detailed insights into the neurological effects of COVID-19.

The exemption allows more time for partners to adhere to enhanced distribution security requirements in the Food, Drug, & Cosmetics Act and prevents possible supply chain disruptions.

CAR T-cell therapy on an outpatient basis could lead to greater adherence and less financial and physical burdens.

The regulatory action is based on a positive preliminary analysis of the VANTAGE trial.

The discovery marks the first time an antibody has been observed to both assist and block viral infection with SARS-CoV-2.

Vaccine gap closure programs in Missouri and California provide a blueprint for a successful campaign.

Though both treatments come with positives and negatives, ultimately, individual patient clinical presentation and accessibility will determine the proper treatment for myasthenic crisis.

Significant polarization surrounding COVID-19 vaccinations in late 2020 and early 2021 looked to have had an impact in increasing vaccine hesitancy.

The results show promise for the use of Bruton tyrosine kinase inhibitors in non-Hodgkin lymphoma treatment.

The treatment aims to reduce prolonged QTc interval in patients with long QT syndrome.

The new screening test provides an easier, convenient option for patients seeking to screen themselves for colorectal cancer.

Major biomarkers for cognitive impairment were observed in hospitalized patients with neurological symptoms.

By utilizing a lower dose, patients can avoid potential adverse events and high financial burden.

As American Pharmacists Month begins, Alan Corley talks the importance of pharmacists and the value of the profession personally and to the overall community.

Positive trial results laid the groundwork for the designation.

Patients exhibited improved disease-free progression with minimal adverse effects.

The weight loss drug continues to show promise in treating a variety of other conditions.

The guidelines mark a shift in practice by recommending a multimodal approach to opioid prescribing practices.

There was a detrimental relationship between COVID-19 caseload and mortality observed across multiple types of hospitals.

Poorer prognosis was linked to factors such as reduced hemoglobin levels and advanced stage at diagnosis.

Although the investigators commonly detected treatment-emergent resistant variants, they were rare and transient in nature.

Alan Corley, pharmacy owner in Greenville, TN, reflects on the changes he's witnessed throughout his career and the most rewarding aspects of his profession.

These interim trial results support the ongoing phase 3 ITHACA trial.

Promising depth of response and consistent safety profile support the use of talquetamab as a combination agent.

Although disease screening reached high-risk patients, uptake was low, necessitating additional incentive to participate in voluntary testing.

These results indicate the combination’s long-term effectiveness in a population with limited treatment options.

The approval marks the only FDA-approved stand-alone therapy for the treatment of Niemann-Pick disease type C (NPC).

Long-term shedding of mutated variants could pose a concern for spread among the public.

As the end of the DSCSA stabilization period approaches, Josh Bolin from the NABP provides an overview of what to expect.